Difference between revisions of "Sunitinib (Sutent)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]</ref><ref>[http://hemonc.org/d...") |
|||
| Line 1: | Line 1: | ||
| + | Also known as SU11248. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/sunitinib.pdf Sunitinib (Sutent) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=607 Sunitinib (Sutent) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/sunitinib.pdf Sunitinib (Sutent) package insert (locally hosted backup)]</ref><ref>[http://sutent.com/ Sutent manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=607#page=26 Sunitinib (Sutent) package insert PDF pages 26-29]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/sunitinib.asp Sunitinib (Sutent) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sunitinib-patient-drug-information Sunitinib (Sutent) patient drug information (UpToDate)]</ref> | ||
Revision as of 21:32, 24 February 2012
Also known as SU11248.
General information
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including: vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and RET. Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Sunitinib (Sutent) package insert PDF pages 26-29[1]
- Sunitinib (Sutent) patient drug information (Chemocare)[4]
- Sunitinib (Sutent) patient drug information (UpToDate)[5]